[go: up one dir, main page]

DE69840169D1 - Arzneimittel zubereitung enthaltend 2-amino-2-ä2-(4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid - Google Patents

Arzneimittel zubereitung enthaltend 2-amino-2-ä2-(4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid

Info

Publication number
DE69840169D1
DE69840169D1 DE69840169T DE69840169T DE69840169D1 DE 69840169 D1 DE69840169 D1 DE 69840169D1 DE 69840169 T DE69840169 T DE 69840169T DE 69840169 T DE69840169 T DE 69840169T DE 69840169 D1 DE69840169 D1 DE 69840169D1
Authority
DE
Germany
Prior art keywords
octylphenyl
saccharide
lecithin
diol
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69840169T
Other languages
English (en)
Inventor
Atsushi Sakai
Rumiko Masuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE69840169D1 publication Critical patent/DE69840169D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69840169T 1997-02-27 1998-02-25 Arzneimittel zubereitung enthaltend 2-amino-2-ä2-(4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid Expired - Lifetime DE69840169D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4366897 1997-02-27
PCT/JP1998/000755 WO1998037875A1 (fr) 1997-02-27 1998-02-25 Composition medicamenteuse

Publications (1)

Publication Number Publication Date
DE69840169D1 true DE69840169D1 (de) 2008-12-11

Family

ID=12670236

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69840169T Expired - Lifetime DE69840169D1 (de) 1997-02-27 1998-02-25 Arzneimittel zubereitung enthaltend 2-amino-2-ä2-(4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid

Country Status (18)

Country Link
US (1) US6277888B1 (de)
EP (2) EP0990440B1 (de)
JP (1) JP4153563B2 (de)
KR (1) KR20000075745A (de)
CN (1) CN1178653C (de)
AT (1) ATE412407T1 (de)
AU (1) AU735406B2 (de)
BR (1) BR9811453A (de)
CA (1) CA2282378C (de)
DE (1) DE69840169D1 (de)
DK (1) DK0990440T3 (de)
ES (1) ES2317663T3 (de)
IL (1) IL131608A (de)
NZ (1) NZ337823A (de)
PT (1) PT990440E (de)
RU (1) RU2188004C2 (de)
SI (1) SI0990440T1 (de)
WO (1) WO1998037875A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
JP4627356B2 (ja) 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
CA2421893A1 (en) 2000-08-31 2002-03-07 Merck And Co., Inc. Phosphate derivatives as immunoregulatory agents
EP1471054B1 (de) * 2002-01-11 2009-07-01 Daiichi Sankyo Company, Limited Aminoalkoholderivat oder phosphonsäurederivat und diese enthaltende medizinische zusammensetzung
DE602004017847D1 (de) * 2003-04-08 2009-01-02 Novartis Ag Feste pharmazeutische darreichungsformen mit einem s1p rezeptoragonisten und einem zuckeralkohol
RU2233163C1 (ru) * 2003-04-30 2004-07-27 Государственное учреждение "Нижегородский научно-исследовательский кожно-венерологический институт" Способ лечения акантолитической пузырчатки
GB0329498D0 (en) * 2003-12-19 2004-01-28 Novartis Ag Organic compounds
KR20110136901A (ko) 2004-02-24 2011-12-21 상꾜 가부시키가이샤 아미노 알코올 화합물
RU2402324C2 (ru) * 2004-07-30 2010-10-27 Новартис Аг Композиции на основе соединений 2-амино-1,3-пропандиола
ES2495690T3 (es) * 2004-11-29 2014-09-17 Novartis Ag Régimen de dosificación de un agonista del receptor S1P
EP1679065A1 (de) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Zubereitung mit kontrollierter Freisetzung von Interferon auf PEGT/PBT-Block-Copolymer-Basis
SG165364A1 (en) * 2005-09-09 2010-10-28 Novartis Ag Treatment of autoimmune diseases
EP1923055A1 (de) * 2006-09-26 2008-05-21 Novartis AG Gefriergetrocknete pharmazeutische Zusammensetzung mit einem S1P Agonisten oder Modulator
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP2465492B1 (de) 2007-10-12 2015-07-01 Novartis AG Zusammensetzung mit Sphingosin-I-Phosphat (SIP)-Rezeptormodulatoren
DK2278960T4 (da) 2008-03-17 2020-01-27 Actelion Pharmaceuticals Ltd Dosisregimen til en selektiv sip1 receptoragonist
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
RU2483749C2 (ru) * 2011-04-15 2013-06-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде биопленки
RU2483748C2 (ru) * 2011-04-15 2013-06-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде пластыря
WO2013020069A1 (en) * 2011-08-03 2013-02-07 Ma Zhongmin Treatment of type 2 diabetes with fty720
CA2920758A1 (en) * 2013-07-29 2015-02-05 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612993B2 (de) 1973-09-03 1981-03-25
US4020159A (en) * 1974-10-08 1977-04-26 Apotheker A. Herbert K.G., Fabrik Pharmazeutischer Praparate Wiesbaden Methods of and medications for treating cardiac disorders by using strophanthin
JPS5562010A (en) * 1978-10-31 1980-05-10 Ajinomoto Co Inc Fat emulsion for intravenous injection
AU5078885A (en) * 1984-12-20 1986-06-26 Warner-Lambert Company Non-irritant detergent
JPS61172814A (ja) * 1985-01-25 1986-08-04 Ss Pharmaceut Co Ltd 安定な低溶血性ビタミンｅ注射液
JPS63152327A (ja) * 1987-11-20 1988-06-24 Toyama Chem Co Ltd 脂肪乳剤から成る溶血防止用組成物を含有する製剤
JPH01172814A (ja) 1987-12-26 1989-07-07 Canon Inc レーザーユニット
AU6461090A (en) 1989-10-30 1991-05-02 Abbott Laboratories Injectable formulation for lipophilic drugs
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
JPH04173736A (ja) * 1990-11-06 1992-06-22 Nippon Shinyaku Co Ltd 乳化剤
KR0155015B1 (ko) * 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
JPH06340525A (ja) 1993-06-02 1994-12-13 Lion Corp 安定な低眼刺激性ビタミンａ類可溶化点眼剤
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
JP3870419B2 (ja) 1994-08-22 2007-01-17 三菱ウェルファーマ株式会社 ベンゼン化合物およびその医薬としての用途
JP3169807B2 (ja) 1995-09-18 2001-05-28 本田技研工業株式会社 ロータ組み付け装置
PT812588E (pt) * 1995-12-28 2005-01-31 Mitsubishi Pharma Corp Composicao farmaceutica externa para administracao topica contendo 2-amino-2-(2-(4-octilfenil)-etil)-propano-1,3-diol para o tratamento de doencas provocadas por uma afeccao imunitaria
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
KR100190826B1 (ko) * 1996-08-26 1999-06-01 강재헌 적혈구 용혈 억제용 약제학적 조성물 및 그의제조방법

Also Published As

Publication number Publication date
EP2030614A1 (de) 2009-03-04
NZ337823A (en) 2001-04-27
IL131608A0 (en) 2001-01-28
CN1253499A (zh) 2000-05-17
ATE412407T1 (de) 2008-11-15
WO1998037875A1 (fr) 1998-09-03
DK0990440T3 (da) 2009-02-23
EP0990440B1 (de) 2008-10-29
CN1178653C (zh) 2004-12-08
BR9811453A (pt) 2000-09-12
SI0990440T1 (sl) 2009-04-30
IL131608A (en) 2003-02-12
CA2282378C (en) 2008-12-30
HK1027959A1 (en) 2001-02-02
EP0990440A1 (de) 2000-04-05
CA2282378A1 (en) 1998-09-03
AU735406B2 (en) 2001-07-05
EP0990440A4 (de) 2004-04-21
KR20000075745A (ko) 2000-12-26
RU2188004C2 (ru) 2002-08-27
ES2317663T3 (es) 2009-04-16
HK1027039A1 (en) 2001-01-05
AU6115598A (en) 1998-09-18
PT990440E (pt) 2009-02-05
US6277888B1 (en) 2001-08-21
JP4153563B2 (ja) 2008-09-24

Similar Documents

Publication Publication Date Title
DE69840169D1 (de) Arzneimittel zubereitung enthaltend 2-amino-2-ä2-(4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid
PT812588E (pt) Composicao farmaceutica externa para administracao topica contendo 2-amino-2-(2-(4-octilfenil)-etil)-propano-1,3-diol para o tratamento de doencas provocadas por uma afeccao imunitaria
PT1050301E (pt) Composições medicinais contendo 2-amino-2-[2-(4- octilfenil)etil]propano-1,3-diol
PT1002792E (pt) Compostos de 2-aminopropano-1,3-diol, sua utilizacao medicinal e intermediariosda sintese dos mesmos
DE59902055D1 (de) Zweiteilige kapsel zur aufnahme von pharmazeutischen zubereitungen für pulverinhalatoren
ES2179910T3 (es) Modificacion cristalina del cdch, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
RU99120398A (ru) Фармацевтическая композиция
HUP0004375A2 (hu) Azelainsavat tartalmazó kompozíció
ITRM940570A0 (it) "sale della l-carnitina e composizioni farmaceutiche che lo contengonoper il trattamento di affezioni cutanee"
HUP0202525A2 (hu) Mofetil mikofenolát és PEG-IFN-alfa együttes alkalmazása, valamint az azokat tartalmazó gyógyszerkészítmények és kit
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
FI982689L (fi) 2-fenyyli-1,2-bentsoisoselenatsol-3(2H)-onin käyttö Alzheimerin taudin käsittelyyn tarkoiettujen farmaseuttisten valmisteiden valmistukseen
CA2340734A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
ITRM940571A0 (it) "sale della l-carnitina e composizioni farmaceutiche che lo contengonoper il trattamento di affezioni cutanee"
HUP9901303A2 (hu) Gyógyszerkészítmény autoimmun betegségek kezelésére
BR9810452A (pt) Nova combinação de medicamentos contra asma
BR9712033A (pt) Composição farmacêutica para tratamento de doenças virais.
DE69739190D1 (de) Arzneimittel zur behandlung von oculären kreislauferkrankungen
EA200401295A1 (ru) Статиновая терапия для усиления поддержания когнитивной функции
NO20001895L (no) Anvendelse av glykosaminoglykaner for fremstilling av farmasøytiske preparater for behandling av diabetes assosierte- øyesykdommer
DK0704219T3 (da) Anvendelse af faktor for osteoblastisk celledeling
ATE12649T1 (de) Optisch aktives dipeptide, seine pharmazeutisch vertraeglichen salze, verfahren zur herstellung und diese enthaltende pharmazeutische praeparate.
ATE134135T1 (de) Ein imidazobenzodiazepin zur behandlung von schlafstörungen
UA30143A (uk) Лікувальний препарат для профілактики та лікування інфекційних та запальних захворювань
RU2001123675A (ru) Средство бальзам "ГРААЛЬ" для лечения сердечно-сосудистой системы и заболеваний крови человека

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN